Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lymphoma, B-Cell × Dexamethasone × Clear all

Phase

Phase 1 4 Phase 1/2 3 Phase 2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Multiple Myeloma 8 Leukemia 6 Lung Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Recurrence 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms, Plasma Cell 2 Lymphoma 2 Leukemia, T-Cell 2 Burkitt Lymphoma 2 Waldenstrom Macroglobulinemia 1 Vomiting 1 Uterine Cervical Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Mouth Neoplasms 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Leukemia, Myeloid, Acute 1 Fatigue 1 Congenital Abnormalities 1 Breast Neoplasms 1 Breast Carcinoma In Situ 1

Interventions

Rituximab 2 loncastuximab tesirine 1 etoposide phosphate 1 blinatumomab 1 Tubercidin 1 Immunotherapy, Adoptive 1 Ifosfamide 1 Etoposide 1 Dexamethasone 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05991388 2026-02-20

Glo-BNHL

University of Birmingham

Phase 2/3 Recruiting

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡